On September 10th, Apeloa Pharmaceutical's CDMO research and development center, APELOA PHARMA SOLUTIONS (referred to as APS) established in Boston, officially began operations. The Boston CDMO research and development center is Apeloa Pharmaceutical's first overseas research and development center, which will focus on providing customers with services such as exploring preclinical process chemical routes and toxicology batch kilogram synthesis. Based on the continued expansion of the small molecule business, it will further expand the layout in cutting-edge technology areas such as peptides and ADC.
普洛药业波士顿研发中心正式投入运营
apeloa pharmaceutical Boston R&D Center officially put into operation
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.